<DOC>
	<DOCNO>NCT00329238</DOCNO>
	<brief_summary>The general aim study determine comparative safety efficacy dabigatran etexilate administer orally warfarin ( International Normalized Ratio ( INR ) 2.0-3.0 ) long-term treatment secondary prevention symptomatic venous thromboembolism patient successfully treated standard dose approve anticoagulant three twelve month confirm acute symptomatic Venous Thrombo-embolism .</brief_summary>
	<brief_title>Secondary Prevention Venous Thrombo Embolism ( VTE ) .</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion : Inclusion_Criteria Acute symptomatic deep vein thrombosis ( DVT ) Pulmonary embolism ( PE ) 312 month prior screen , document objective test Exclusion criterion : Exclusion_Criteria Symptomatic DVT PE screen Interruption anticoagulant therapy 2 week 312 month treatment prior VTE . Patients investigator judgement perceive excessive risk bleeding Elevated Aspartate aminotransferase ( AST ) Alanine tranminase ( ALT ) &gt; 2x ULN Severe renal impairment ( estimate creatinine clearance &lt; = 30 ml/min )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>